



## Voyager Therapeutics Announces Management Change

05/29/18

CAMBRIDGE, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced that Jane Henderson, Voyager's chief financial officer and senior vice president of corporate development, has advised the Company of her intent to pursue other career opportunities that are closer to home and plans to leave the company June 8, 2018. Allison Dorval, vice president of finance, will assume the roles of principal financial officer and principal accounting officer.

"On behalf of the Board and our leadership team here at Voyager, I would like to thank Jane for her role in strengthening our financial operations, improving our capital structure, and helping to drive our ongoing business development activities including our recent successful collaboration with AbbVie," said Steve Paul, M.D., president and chief executive officer of Voyager. "Voyager is well-positioned as we approach our pivotal program for Parkinson's disease and continue to advance our pipeline programs, and we thank Jane for her leadership in support of these initiatives and our programs."

Ms. Henderson added, "It has been a privilege to work with such a highly productive and dedicated team at Voyager. As I turn my career objectives towards other opportunities that are closer to home and my family, I am pleased to have contributed to Voyager's recent success and progress and to have been part of an extraordinary team."

### About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. Voyager's pipeline focuses on severe neurological diseases in need of effective new therapies, including Parkinson's disease, a monogenic form of ALS called SOD1, Huntington's disease, Friedreich's ataxia, neurodegenerative diseases related to defective or excess aggregation of tau protein in the brain including Alzheimer's disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, AbbVie, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit [www.voyagertherapeutics.com](http://www.voyagertherapeutics.com).

### Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "undoubtedly," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding the initiation, timing, progress and reporting of results of its preclinical programs and clinical trials and its research and development programs, its ability to advance its AAV-based gene therapies into, and successfully initiate, enroll and complete, clinical trials, the potential clinical utility of its product candidates, its ability to continue to develop its gene therapy platform, its ability to develop manufacturing capability for its products and successfully transition its manufacturing process, its ability to perform under existing collaborations with, among others, Sanofi Genzyme and AbbVie and to add new programs to its pipeline, its ability to enter into new partnerships or collaborations, and the timing or likelihood of its regulatory filings and approvals, are forward looking. All forward-looking statements are based on estimates and assumptions by Voyager's management that, although Voyager believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the initiation and conduct of preclinical studies and clinical trials; the availability of data from clinical trials; the expectations for regulatory submissions and approvals; the continued development of the gene therapy platform; Voyager's scientific approach and general development progress; and the availability or commercial potential of Voyager's product candidates. These statements are also subject to a number of material risks and uncertainties that are described in Voyager's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

### Investor Relations:

Matt Osborne

Vice President of Investor Relations & Corporate Communications

857-259-5353 ☐

[mosborne@vygr.com](mailto:mosborne@vygr.com)

### Media:

Elliot FoxW2O Group ☐

212-257-6724 ☐

[efox@w2ogroup.com](mailto:efox@w2ogroup.com)



Source: Voyager Therapeutics, Inc.